Please assess the completion status of the following clinical trial:

Trial Title: HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ages 10 years old and above~2. Patients who are newly diagnosed with high-risk acute lymphoblastic leukemia~3. Patients who have started or will start an induction chemotherapy regimen containing steroid and asparaginase~4. Patients (if over 18 years of age) or parent/guardian (if the patient is under 18 years of age) must be fluent in reading and speaking English~5. Parent or guardian living in the home with the participant who also receives training on diabetes, CGM, HCL therapy, and the safety protocols~Exclusion Criteria:~1. Preexisting diabetes~2. Severe psychiatric disease or developmental delays, that might interfere with ability to provide informed consent~3. Active skin condition that would affect sensor placement~4. Any other medical condition which in the opinion of the investigators impairs the person's ability to safely participate in the trial, including but limited to:~   1. Significant chronic kidney disease (eGFR \<60) or requiring hemodialysis~  2. Significant liver disease~  3. History of adrenal insufficiency~  4. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated~  5. History of thyroid cancer~5. Use of intravenous or oral acetaminophen more than 60 mg/kg/day (maximum 4000 mg/day)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase (Type: EXPERIMENTAL): Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).